John Klein
Equity Research
LONDON – 01 June 2022: Bryan Garnier & Co, the leading independent investment bank for European healthcare and technology-related companies and their investors, today announced that John Klein has been appointed as the investment bank’s new Head of Equity Research.
John is a seasoned financial markets expert with experience across investment banking, equity research, private equity and corporates. He joins from Zalando, where he was Senior Business Developer with responsibility for driving the company’s capital markets communication strategy. Prior to this, John was responsible for capital raising at DTCP, a private and growth equity investment firm. John was previously a Director at Feros Advisers in London, a boutique capital markets advisory, and Head of Chemicals Research at Berenberg. John holds a postgraduate Master’s degree in Finance from ESCP-Europe, as well as a Master’s degree in International Economics from the University of Innsbruck.
Olivier Garnier, Founder and Managing Partner of Bryan Garnier said: “We are delighted to welcome John as our new Head of Research. His breadth of experience across the private and public markets makes him the ideal choice to enhance Bryan Garnier’s research and thought leadership offering consistent with our mission to provide clients with highly differentiated insights across the key growth sectors of the economy that create value. John’s appointment marks the beginning of a new phase of Bryan Garnier research that will capitalise not only on our analysts’ deep sector knowledge and strong relationships with investors, but their unique ability to connect the dots between what is happening in the public and private markets.”
John Klein, Head of Research at Bryan Garnier said: “I am thrilled to be joining Bryan Garnier in order to lead a fantastic team of analysts who are true sector-specialists across healthcare, technology and sustainability. As an established full service investment bank with a strong foothold in both the European public and private markets, Bryan Garnier is uniquely positioned to provide unparalleled insights and give an important edge to our clients including institutional investors, corporates and financial sponsors.”
In its 25th year, full service investment bank, Bryan Garnier, provides equity coverage on over 200 listed growth stocks in Europe and delivers thought leadership through whitepapers, sector reports, events and webinars that showcase hot areas of innovation and investment. The firm is relentless in its pursuit of new and disruptive investable themes across healthcare and technology-related sectors and was one of the first investment banks to focus on MRNA, hydrogen and insect protein. Having held senior roles across a variety of functions, John brings with him a wealth of experience and will help to shape the future of Bryan Garnier’s research offering.
Bryan Garnier recently launched On the Money, a monthly webinar series where a Bryan Garnier analyst is joined by a leading financial sponsor to discuss some of the most exciting investment themes across technology, healthcare and sustainability. The first webinar will feature Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners and they will be discussing what’s hot in biotech right now. The webinar will take place on 8 June at 10am BST. To register, please visit: https://www.bryangarnier.com/webinar-on-the-money/
About Bryan, Garnier & Co
Bryan Garnier is a leading independent investment bank specializing in healthcare and technology-led companies in Europe. Our clients benefit from our deep industry knowledge, global perspective, and strong relationships with investors spanning private equity, venture capital, and institutional investors across the US, Europe, and Asia. Our corporate clients are disruptors operating in high-growth sectors focused on solving sustainability challenges. As a sector-driven investment bank, we offer full-service solutions, including access to public and private capital, M&A advisory, and equity research. Our partnership approach provides clients with tailored ideas and flawless execution to accelerate their long-term success. Our equity research team provides differentiated insights and investment themes to give our clients a competitive edge. Our independence and entrepreneurial culture ensure complete alignment with our clients, and our purpose is to help European pioneers become global champions. Clients choose Bryan Garnier as their long-term partner for our commitment to their success and unparalleled industry expertise.